Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
0.4594
+0.0195 (4.43%)
At close: Nov 3, 2026, 4:00 PM EST
0.4499
-0.0095 (-2.07%)
After-hours: Nov 3, 2026, 4:15 PM EST
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $1.50M in the quarter ending June 30, 2026, a decrease of -43.79%. This brings the company's total for the last twelve months to $10.04M, up 10.02% year-over-year. In the year 2025, Caribou Biosciences had annual revenue of $11.16M with 11.66% growth. That makes Caribou Biosciences the 37,369th largest company in the world by revenue and 4,896th in the United States.
Revenue (ttm)
$10.04M
Revenue Growth
+10.02%
P/S Ratio
4.77
Revenue / Employee
$103,454
Employees
97
Market Cap
49.25M
Revenue by Geography
- United States 9.48M 84.9%
- Rest of World 1.68M 15.1%
Fiscal year ended Dec 31, 2025 See the full Caribou Biosciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.16M | 1.17M | 11.66% |
| Dec 31, 2024 | 9.99M | -24.48M | -71.01% |
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinium Pharmaceuticals | 35.09M |
| Apollomics | 8.84M |
| Connect Biopharma Holdings | 2.95M |
| Hyperion DeFi | 1.40M |
| ImageneBio | 800.00K |
| Mereo BioPharma Group | 500.00K |
CRBU News
- 26 days ago - Caribou Biosciences moved to No Rating at BofA - TheFly
- 26 days ago - Caribou Biosciences downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 27 days ago - Why is Caribou Biosciences Stock (CRBU) Down 43% Today? - TipRanks
- 27 days ago - Caribou Biosciences downgraded to Market Perform from Outperform at Leerink - TheFly
- 27 days ago - Caribou Biosciences downgraded to Sector Perform from Outperform at RBC Capital - TheFly
- 27 days ago - Caribou Biosciences downgraded to Hold from Buy at Brookline - TheFly
- 4 weeks ago - Caribou Biosciences trading resumes - TheFly
- 4 weeks ago - Caribou to discontinue development activities, explore alternatives - TheFly